Publication Name	World Journal of Gastrointestinal Endoscopy
Manuscript ID	74645
Country	United States

Received	2021-12-31 01:13
Peer-Review Started	2021-12-31 01:15
To Make the First Decision
Return for Revision	2022-01-24 02:10
Revised	2022-02-14 00:50
Second Decision	2022-04-12 01:58
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-04-21 18:13
Articles in Press	2022-04-21 18:13
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-04-24 01:58
Publish the Manuscript Online	2022-05-16 10:48

ISSN	1948-5190 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms
Manuscript Source	Invited Manuscript
All Author List	Andrew Canakis and Linda S Lee
Funding Agency and Grant Number
Corresponding Author	Linda S Lee, MD, Associate Professor, Director, Division of Gastroenterology Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, United States. llee@bwh.harvard.edu
Key Words	Gastroenteropancreatic neuroendocrine neoplasms; Neuroendocrine tumors; Neuroendocrine carcinoma; Gastrointestinal; Pancreas; Small intestine
Core Tip	Diagnostic technology for neuroendocrine tumors continues to advance. Radiomics promises to enhance morphologic imaging. Gallium-68 DOTA-peptide positron emission tomography/computed tomography has replaced Octreoscan as the preferred functional imaging modality. Newer radiolabeled peptides may further improve detection. A novel liquid biopsy biomarker (NETest) has proven more accurate than chromogranin A in monitoring treatment response and predicting disease activity. Therapy has also progressed with treatment adapted based on the predicted behavior of the tumor. Advanced endoscopic resection techniques have revolutionized treatment. Preliminary evidence suggests endoscopic ultrasound guided radiofrequency ablation may prove useful in treating pancreatic lesions. Multimodality therapy continues to evolve for metastatic pancreatic tumors.
Publish Date	2022-05-16 10:48
Citation	Canakis A, Lee LS. Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Endosc 2022; 14(5): 267-290
URL	https://www.wjgnet.com/1948-5190/full/v14/i5/267.htm
DOI	https://dx.doi.org/10.4253/wjge.v14.i5.267

Full Article (PDF)	WJGE-14-267.pdf
Full Article (Word)	WJGE-14-267.docx
Manuscript File	74645_Auto_Edited.docx
Answering Reviewers	74645-Answering reviewers.pdf
Audio Core Tip	74645-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	74645-Conflict-of-interest statement.pdf
Copyright License Agreement	74645-Copyright license agreement.pdf
Peer-review Report	74645-Peer-review(s).pdf
Scientific Editor Work List	74645-Scientific editor work list.pdf